Cost of heart failure to the healthcare system.
From an economic, mortality, and functional standpoint, heart failure is clearly a disease that needs to be targeted. We can develop a model for heart failure to determine the impact that specific management strategies will have on the overall cost to the system, which by itself can tell us some interesting things because we're currently spending twice as much on transplantation as on digoxin therapy. We can then use this model to assess the impact of different strategies, such as greater use of angiotensin-converting enzyme (ACE) inhibitors or digoxin therapy.
Mackowiak
J
J
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use; D002303:Cardiac Output, Low / Q000191:economics* / Q000503:physiopathology / Q000628:therapy; D016507:Cardiology Service, Hospital / Q000191:economics; D017046:Cost Savings; D017281:Cost of Illness; D004077:Digoxin / Q000191:economics / Q000627:therapeutic use; D004232:Diuretics / Q000191:economics / Q000627:therapeutic use; D004638:Emergency Treatment / Q000191:economics; D006321:Heart; D016027:Heart Transplantation / Q000191:economics; D006801:Humans; D009819:Office Visits / Q000191:economics; D011788:Quality of Life; D014481:United States
D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D004077:Digoxin